Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
NCT01631474 is registered in ClinicalTrials.gov with Intrepid Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
- Lead sponsor
- Intrepid Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2012
- Completion date
- February 28, 2014
- Enrollment
- 363 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.